Abbott to Acquire Exact Sciences for $23 Billion

Abbott to acquire Exact Sciences for $105 per share in cash.

The acquisition is valued at approximately $23 billion, including Exact Sciences' net debt.

Exact Sciences is projected to generate over $3 billion in revenue this year.

The deal is expected to close in the second quarter of 2026, subject to shareholder and regulatory approvals.

The acquisition will add a new growth vertical to Abbott’s portfolio, gaining leadership in the U.S. cancer screening and precision oncology diagnostics segments, valued at $60 billion. Why this matters: This acquisition positions Abbott to transform cancer care by advancing earlier detection and optimizing treatment strategies, potentially impacting millions of lives.

Cologuard®: A noninvasive colorectal cancer screening test.

Oncotype DX®: Informs personalized treatment decisions for breast cancer patients.

Oncodetect™: Identifies molecular residual disease (MRD) to assess cancer recurrence risk.

Cancerguard™: A multi-cancer early detection blood test.

Q: What is the value of the acquisition?

Q: When is the deal expected to close?

Q: What will happen to Exact Sciences after the acquisition?

Abbott’s acquisition of Exact Sciences signifies a major advancement in cancer diagnostics and personalized treatment.

The combined entity aims to improve early cancer detection and management, potentially saving lives.

Investors can anticipate revenue growth and margin expansion for Abbott following the acquisition.

Exact Sciences’ shareholders will receive $105 per share in cash.